Skip to main content
. 2013 Jan 26;17(1):9–19. doi: 10.1007/s40291-013-0018-7

Fig. 1.

Fig. 1

Recurrence-free survival in small-bowel gastrointestinal stromal tumors (GISTs), according to National Comprehensive Cancer Network (NCCN)–Armed Forces Institute of Pathology (AFIP) risk categories (based on the authors’ own data from 659 primary GISTs after radical resection, presented during the European Society of Surgical Oncology conference [100])